Back to CVE records
Critical 9.3Published Sep 11, 2026

CVE-2026-54072Authorizer: Unvalidated redirect_uri in /authorize leaks OAuth2 tokens to attacker-controlled URL

Updated under an hour ago ()

Does this affect you?

It affects authorizerdev authorizer. Add what you run to find out whether that includes you.

No exploitation reported and no EPSS estimate yet.

Authorizer is an open-source, self-hostable authentication and authorization server. Prior to version 2.2.1, the `/authorize` endpoint accepts any `redirect_uri` without validating it against `AllowedOrigins`. When `response_type=token` or `response_type=id_token`, the server appends `access_token`, `id_token`, and `refresh_token` as query parameters and issues a 302 redirect to the attacker-supplied URL. An unauthenticated attacker can obtain the required `client_id` from the public `/graphql?query={meta{client_id}}` endpoint. A partial fix was applied in v2.0.1 to other handlers (`oauth_login`, `verify_email`, `magic_link_login`, `forgot_password`, `invite_members`, `oauth_callback`) but `/authorize` was not included. Version 2.2.1 contains a more complete fix.

CVSS
9.3 CRITICAL (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:H/A:N
Weakness (CWE)
CWE-601
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
GitHub_M
NVD analysis
Deferred
Record last updated
Sep 15, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

Affected products
authorizerdev authorizer
authorizerdev:authorizer (from the name)
before 2.2.1
CNA record

References

  • x-refsource-confirm

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.